Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.

Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ.

J Clin Pharmacol. 2019 Jul 19. doi: 10.1002/jcph.1480. [Epub ahead of print]

PMID:
31322739
2.

Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults.

Ali SO, Yu XQ, Robbie GJ, Wu Y, Shoemaker K, Yu L, DiGiandomenico A, Keller AE, Anude C, Hernandez-Illas M, Bellamy T, Falloon J, Dubovsky F, Jafri HS.

Clin Microbiol Infect. 2019 May;25(5):629.e1-629.e6. doi: 10.1016/j.cmi.2018.08.004. Epub 2018 Aug 11.

3.

Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus.

Greth W, Robbie GJ, Brohawn P, Hultquist M, Yao B.

Immunotherapy. 2017 Jan;9(1):57-70. doi: 10.2217/imt-2016-0090. Review.

PMID:
28000522
4.

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults.

Yu XQ, Robbie GJ, Wu Y, Esser MT, Jensen K, Schwartz HI, Bellamy T, Hernandez-Illas M, Jafri HS.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01020-16. doi: 10.1128/AAC.01020-16. Print 2017 Jan.

5.

Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.

Pishvaian M, Morse MA, McDevitt J, Norton JD, Ren S, Robbie GJ, Ryan PC, Soukharev S, Bao H, Denlinger CS.

Clin Colorectal Cancer. 2016 Dec;15(4):345-351. doi: 10.1016/j.clcc.2016.07.009. Epub 2016 Aug 4.

PMID:
27591895
6.

Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.

Zheng B, Yu XQ, Greth W, Robbie GJ.

Br J Clin Pharmacol. 2016 May;81(5):918-28. doi: 10.1111/bcp.12864. Epub 2016 Mar 4.

7.

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.

Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.

Hum Vaccin Immunother. 2014;10(10):2789-94. doi: 10.4161/hv.29635.

8.

Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation.

Robbie GJ, Makari D, Harris B, Losonsky GA, Jafri HS.

Infect Dis Ther. 2014 Dec;3(2):203-14. doi: 10.1007/s40121-014-0042-x. Epub 2014 Sep 30.

9.

Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia.

Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, Keller A, O'Day T, Du Q, Cheng L, Damschroder M, Robbie G, Suzich J, Stover CK, Sellman BR.

Antimicrob Agents Chemother. 2014;58(2):1108-17. doi: 10.1128/AAC.02190-13. Epub 2013 Dec 2.

10.

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.

Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP.

Antimicrob Agents Chemother. 2013 Dec;57(12):6147-53. doi: 10.1128/AAC.01285-13. Epub 2013 Sep 30.

11.

Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.

Narwal R, Roskos LK, Robbie GJ.

Clin Pharmacokinet. 2013 Nov;52(11):1017-27. doi: 10.1007/s40262-013-0085-2.

12.

Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.

La Via WV, Notario GF, Yu XQ, Sharma S, Noertersheuser PA, Robbie GJ.

Pulm Pharmacol Ther. 2013 Dec;26(6):666-71. doi: 10.1016/j.pupt.2013.03.007. Epub 2013 Mar 19.

13.

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.

Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, Neuwelt CM, Robbie G, White WI, Higgs BW, Yao Y, Wang L, Ethgen D, Greth W.

Arthritis Rheum. 2013 Apr;65(4):1011-21. doi: 10.1002/art.37824.

14.

Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.

Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK.

Antimicrob Agents Chemother. 2012 Sep;56(9):4927-36. doi: 10.1128/AAC.06446-11. Epub 2012 Jul 16. Erratum in: Antimicrob Agents Chemother. 2012 Oct;56(10):5431.

15.

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.

Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R.

Invest New Drugs. 2013 Feb;31(1):77-84. doi: 10.1007/s10637-012-9801-2. Epub 2012 Feb 28.

16.

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.

Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B; Lupus Interferon Skin Activity (LISA) Study Investigators.

Ann Rheum Dis. 2011 Nov;70(11):1905-13. doi: 10.1136/ard.2010.144485. Epub 2011 Jul 27.

PMID:
21798883
17.

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma.

Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, Robbie GJ, White WI, White B, Molfino NA; MEDI-528 Clinical Trials Group.

BMC Pulm Med. 2011 Feb 28;11:14. doi: 10.1186/1471-2466-11-14.

18.

A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis.

Bissonnette R, Papp K, Maari C, Yao Y, Robbie G, White WI, Le C, White B.

J Am Acad Dermatol. 2010 Mar;62(3):427-36. doi: 10.1016/j.jaad.2009.05.042.

PMID:
20159310
19.

Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.

White B, Leon F, White W, Robbie G.

Clin Ther. 2009 Apr;31(4):728-40. doi: 10.1016/j.clinthera.2009.04.019.

PMID:
19446146
20.

Metabolites and bioequivalence: past and present.

Jackson AJ, Robbie G, Marroum P.

Clin Pharmacokinet. 2004;43(10):655-72. Review.

PMID:
15244496
21.

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R.

Clin Cancer Res. 2002 Oct;8(10):3034-8.

22.

Poor and unusually prolonged oral absorption of amphotericin B in rats.

Robbie G, Wu TC, Chiou WL.

Pharm Res. 1999 Mar;16(3):455-8. No abstract available.

PMID:
10213379
24.
25.

Similarity or discrepancy in pharmacokinetic parameter estimation between bolus and infusion studies.

Chiou WL, Chung SM, Robbie G.

J Pharmacokinet Biopharm. 1997 Aug;25(4):471-6.

PMID:
9561489
26.
27.

Influenzal meningitis.

ROBBIE GA, PITNEY WR.

Med J Aust. 1949 Nov 22;2(17):609. No abstract available.

PMID:
15396202
28.

The treatment of pneumococcal meningitis.

ROBBIE GA.

Med J Aust. 1949 Nov 5;2(19):676. No abstract available.

PMID:
15396976

Supplemental Content

Loading ...
Support Center